BEL114333, a Multicenter, Continuation Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase III Study BEL113750 in Northeast Asia or Completed the Open-label Extension of HGS1006-C1115 in Japan
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Mar 2018
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 22 Mar 2018 Planned End Date changed from 31 Aug 2018 to 28 Sep 2018.
- 22 Mar 2018 Planned primary completion date changed from 31 Aug 2018 to 28 Sep 2018.
- 09 Feb 2018 Planned End Date changed from 29 Jun 2018 to 31 Aug 2018.